MAGE-4 (156-163)

MAGE-4 (156-163) is a synthetic peptide fragment corresponding to amino acids 156 to 163 of the melanoma-associated antigen 4 protein. As a member of the MAGE (Melanoma Antigen Gene) family, this peptide is frequently utilized in molecular and cellular studies focused on tumor antigens, immune recognition, and peptide-based assay development. Its defined sequence and biochemical properties make it a valuable tool for researchers investigating antigen processing, T-cell epitope mapping, and the broader mechanisms of antigen presentation in oncology and immunology contexts.

Epitope Mapping: Researchers employ the 156-163 fragment of MAGE-4 in epitope mapping studies to identify and characterize the precise regions of the antigen recognized by cytotoxic T lymphocytes (CTLs). By incorporating this peptide into in vitro assays, scientists can determine the immunodominant epitopes involved in T-cell recognition, which is fundamental for understanding immune surveillance in cancer and for designing targeted immunological experiments.

Antigen Presentation Studies: The peptide serves as an important substrate in investigations of major histocompatibility complex (MHC) class I antigen processing and presentation. Its defined sequence allows for the controlled assessment of peptide binding to MHC molecules, facilitating research into the molecular mechanisms that govern peptide loading, stability, and recognition by T-cell receptors. Such studies are pivotal for elucidating the cellular machinery involved in immune responses to tumor-associated antigens.

Peptide-Based Assay Development: MAGE-4 (156-163) is widely used in the development and optimization of peptide-based immunoassays, including enzyme-linked immunospot (ELISpot) and flow cytometric assays. The peptide's specificity enables the detection and quantification of antigen-specific T-cell responses in experimental systems, supporting immunomonitoring in preclinical research and the evaluation of immune reactivity in various biological samples.

Synthetic Peptide Control: As a chemically defined synthetic peptide, the 156-163 fragment functions as a reliable positive control in peptide functional studies. It is routinely incorporated into experimental protocols to validate assay performance, calibrate detection systems, and benchmark cellular responses, ensuring reproducibility and accuracy in peptide-driven research workflows.

Peptide Engineering and Modification: The sequence of MAGE-4 (156-163) also provides a foundation for peptide engineering applications, such as the design of analogs with altered immunogenicity or enhanced stability. By introducing specific modifications or substitutions, researchers can investigate structure-activity relationships, optimize peptide properties for binding studies, or create novel reagents for probing antigenic determinants. This supports the broader field of peptide-based tool development in molecular immunology and cancer research.

1. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

2. Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans and Candida albicans Clinical Isolates from Children with Early Childhood Caries

3. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

4. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

5. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency